Investigators are encouraged to engage with Apollo Therapeutics if their research is considered at the right stage for a translational approach.
Apollo Therapeutics is a collaborative venture between three world-leading UK universities (UCL, Imperial College London and the University of Cambridge) and three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation), providing translational funding and drug discovery expertise for novel therapeutics to accelerate them towards the clinic. Their model provides independent access to resources to grow innovations and they aim to champion the best of British academic research to industry.
Apollo’s team of industry scientists have a proven track record of therapeutic delivery and work in partnership with academics and industry partners, with the aim to craft each bespoke project to optimise the chances of long-term success.
For more information about Apollo and expertise/funding on offer for collaborative projects contact info@apollotherapeutics.com.
